BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Palverafusp alfa readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Palverafusp alfa\, from ClinicalTrials.go
 v estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07687914-2541@assetmemo.bio
DTSTAMP:20261121T005726Z
DTSTART;VALUE=DATE:20270723
DTEND;VALUE=DATE:20270724
SUMMARY:Palverafusp alfa: Phase 2 readout est. (NCT07687914)
DESCRIPTION:Palverafusp alfa\, phase 2.\nStudy: A Study of IMM2510 + IMM27M
  Combination Therapy in Patients With Advanced Hepatocellular Carcinoma\nE
 stimated primary completion: 23 July 2027. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/palverafusp-alfa#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT07687914
URL:https://assetmemo.bio/drug/palverafusp-alfa#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07170787-2541@assetmemo.bio
DTSTAMP:20261121T005726Z
DTSTART;VALUE=DATE:20290228
DTEND;VALUE=DATE:20290301
SUMMARY:Palverafusp alfa: Phase 1/2 readout est. (NCT07170787)
DESCRIPTION:Palverafusp alfa\, phase 1/2.\nStudy: A Study of IMM2510 + IMM0
 1 Combination Therapy in Patients With Advanced Solid Tumors\nEstimated pr
 imary completion: February 2029. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/palverafusp-alfa#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT07170787
URL:https://assetmemo.bio/drug/palverafusp-alfa#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
